AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
Advanced or Metastatic Solid Tumor|Pancreatic Ductal Adenocarcinoma|Colorectal Cancer|Non-small Cell Lung Cancer|Gastric Cancer|Alveolar Soft Part Sarcoma|Esophageal Cancer|Head and Neck Cancer|Biliary Tract Cancer
DRUG: AB122|DRUG: AB122|DRUG: TAS-116|DRUG: AB122|DRUG: TAS-116|DRUG: AB122|DRUG: TAS-116|DRUG: AB122|DRUG: TAS-120|DRUG: AB122|DRUG: TAS-115|DRUG: AB122|DRUG: TAS-115|DRUG: AB122|DRUG: TAS-102|DRUG: Ramucirumab|DRUG: AB122|DRUG: TAS-102|DRUG: Bevacizumab|DRUG: AB122|DRUG: AB122|DRUG: TAS-120|DRUG: Fluorouracil|DRUG: Cisplatin|DRUG: AB122|DRUG: TAS-120|DRUG: AB154|DRUG: AB122|DRUG: TAS-120|DRUG: Fluorouracil|DRUG: Carboplatin|DRUG: Cisplatin|DRUG: AB122|DRUG: TAS-120|DRUG: AB154|DRUG: AB122|DRUG: TAS-120|DRUG: Carboplatin|DRUG: nab-Paclitaxel|DRUG: AB122|DRUG: TAS-120|DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: AB122|DRUG: TAS-120|DRUG: nab-Paclitaxel|DRUG: Gemcitabine
Phase 1a (All cohorts except Cohort D-4 and D-5) : Percentage of participants who experience a Dose Limiting Toxicity (DLT), From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q2W arm)|Phase 1a (Cohort D-4 and D-5) : Percentage of adverse events and treatment-related adverse events., From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q2W arm)|Phase 1b (Cohort B-n, D-n and E-n) : Objective Response Rate (ORR), Through completion of treatment (estimated up to be 11 months)|Phase 1b (Cohort C-n): The 6-month PFS proportion by RECIST v1.1, Through completion of treatment (estimated up to be 11 months)
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.